Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(21/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(21/week)
News
United States
(584/week)
Manufacturing
(403/week)
Energy
(324/week)
Technology
(409/week)
Other Manufacturing
(343/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Innovent Biologics Inc.
Aug 12, 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Jun 21, 2020
Innovent Announces The Stock Exchange of Hong Kong Limited Approved the "B" Marker Removal from the Company's Stock Symbol in the HKEX
Jun 19, 2020
Innovent Announces the NMPA Granted Marketing Approval for BYVASDA® (Bevacizumab Biosimilar) in China
Jun 18, 2020
Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China
Jun 02, 2020
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
Jun 01, 2020
Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
May 31, 2020
Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
May 31, 2020
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
May 25, 2020
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
May 18, 2020
Innovent Biologics and MD Anderson Announce a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT® (Sintilimab Injection) in Rare Cancers
May 14, 2020
Innovent Announces Key Results from a Number of Clinical Studies to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
May 13, 2020
TYVYT® (Sintilimab Injection) ORIENT-2 Study Met its Primary Endpoint of Overall Survival in the Second-Line Treatment of Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Apr 27, 2020
Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China
Apr 23, 2020
Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum as First-Line Therapy in Non-squamous NSCLC
Apr 19, 2020
Innovent Biologics Announces FDA Approval of Pemazyre(TM) (Pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
Mar 30, 2020
Innovent Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Progress
Mar 25, 2020
Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China
Jan 13, 2020
Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
Page 1
››
Latest News
May 12, 2024
Ørsted and Shipbuilder Edison Chouest Christen First-Ever American-Built, Offshore Wind Service Operations...
May 11, 2024
Pembina Pipeline Corporation Reports Voting Results from 2024 Annual Meeting of Shareholders
May 11, 2024
Terran Orbital Schedules Conference Call to Discuss First Quarter 2024 Financial Results
May 11, 2024
Fonon Corporation Highlights Applications for Its Laser Cutting Technology in the Mining Industry
May 11, 2024
Sky Harbour to Report 2024 Q1 Results and Host Webcast Investor Call Tuesday, May 14, 2024
May 11, 2024
Russia claims more advances after Ukraine ground offensive
May 11, 2024
La Corée du Nord va déployer un nouveau lance-roquettes multiple en 2024
May 11, 2024
SpinLaunch Board Announces Leadership Transition
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events